On November 5, 2014, the U. S. Food and Drug Administration approved
ramucirumab (Cyramza, Eli Lilly and Company) for use in combination with
paclitaxel for the treatment of patients with advanced gastric or
gastroesophageal junction (GEJ) adenocarcinoma. Ramucirumab was
approved in April, 2014 as a single agent for the treatment of patients
with advanced gastric or GEJ adenocarcinoma refractory to or progressive
following first-line therapy with platinum or fluoropyrimidine
chemotherapy.
For more details on approval please CLICK HERE
No comments:
Post a Comment